^
Association details:
| Biomarker: | SETBP1 mutation |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
10/06/2021
Excerpt:
Myelodysplastic…Atypical chronic myeloid leukemia…Frequent mutations: SETBP1, ETNK1; Treatment: Consider HMA and/or ruxolitinib…
